JP2024520020A5 - - Google Patents
Info
- Publication number
- JP2024520020A5 JP2024520020A5 JP2023572876A JP2023572876A JP2024520020A5 JP 2024520020 A5 JP2024520020 A5 JP 2024520020A5 JP 2023572876 A JP2023572876 A JP 2023572876A JP 2023572876 A JP2023572876 A JP 2023572876A JP 2024520020 A5 JP2024520020 A5 JP 2024520020A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- score
- nash
- nash crn
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194088P | 2021-05-27 | 2021-05-27 | |
| US63/194,088 | 2021-05-27 | ||
| PCT/IB2022/054867 WO2022249071A1 (en) | 2021-05-27 | 2022-05-25 | Pemafibrate and/or tofogliflozin for use in treating liver disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520020A JP2024520020A (ja) | 2024-05-21 |
| JP2024520020A5 true JP2024520020A5 (cg-RX-API-DMAC10.html) | 2025-05-08 |
Family
ID=82020168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572876A Pending JP2024520020A (ja) | 2021-05-27 | 2022-05-25 | 肝疾患の治療における使用のためのペマフィブラートおよび／またはトホグリフロジン |
Country Status (10)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2024014524A1 (cg-RX-API-DMAC10.html) * | 2022-07-15 | 2024-01-18 | ||
| CN115991682A (zh) * | 2023-03-21 | 2023-04-21 | 广州佳途科技股份有限公司 | 一种培马贝特-d4的制备方法及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI696462B (zh) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| EP3569250B1 (en) * | 2017-01-11 | 2025-04-30 | Kowa Company, Ltd. | Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease |
-
2022
- 2022-05-25 EP EP22729797.5A patent/EP4346809B1/en active Active
- 2022-05-25 US US18/564,115 patent/US20240277745A1/en active Pending
- 2022-05-25 MX MX2023013886A patent/MX2023013886A/es unknown
- 2022-05-25 BR BR112023024701A patent/BR112023024701A2/pt unknown
- 2022-05-25 CN CN202280050095.0A patent/CN117677385A/zh active Pending
- 2022-05-25 JP JP2023572876A patent/JP2024520020A/ja active Pending
- 2022-05-25 CA CA3221073A patent/CA3221073A1/en active Pending
- 2022-05-25 KR KR1020237044685A patent/KR20240013203A/ko active Pending
- 2022-05-25 AU AU2022282651A patent/AU2022282651A1/en active Pending
- 2022-05-25 WO PCT/IB2022/054867 patent/WO2022249071A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6250588B2 (ja) | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 | |
| JP5869469B2 (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| JP2018507914A5 (cg-RX-API-DMAC10.html) | ||
| KR102876077B1 (ko) | 간 질환을 치료하기 위한 병용 요법 | |
| KR102000332B1 (ko) | 간내 담즙정체성 질환의 치료 | |
| JP7617898B2 (ja) | Ｅｙｐ００１を使用した改善された処置 | |
| CN113301889A (zh) | Nafld和nash的联合治疗 | |
| US20210260025A1 (en) | Capsid assembly modulator dosing regimen | |
| JP2023516505A (ja) | 非アルコール性脂肪性肝炎の治療のためのセマグルチド | |
| JP2024524273A5 (cg-RX-API-DMAC10.html) | ||
| WO2019024758A1 (zh) | 一种糖苷类化合物在制备用于治疗肝纤维化药物中的应用 | |
| JP2024502673A (ja) | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| JP2024500324A5 (cg-RX-API-DMAC10.html) | ||
| JP2001520994A (ja) | 消化管疾患を治療するためにクマリン誘導体を用いる用途 | |
| JP2002524417A5 (cg-RX-API-DMAC10.html) | ||
| JP2022527190A5 (cg-RX-API-DMAC10.html) | ||
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| CN113015525A (zh) | 依达拉奉在非酒精性脂肪肝炎治疗或预防中的应用 | |
| CA3100635A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| CN111084808A (zh) | 咳特灵制剂在治疗乙型肝炎中的应用 | |
| KR102916453B1 (ko) | 오바토클락스 대사성 질환 및 섬유화 질환 치료 용도 | |
| WO2021009333A1 (en) | Synergistic effect of eyp001 and ifn for the treatment of hbv infection | |
| JP2023543131A5 (cg-RX-API-DMAC10.html) | ||
| CN121243146A (zh) | 3,5-二甲氧基-4-(2-氨基-3-(2-炔-丙硫烷)-丙酰基)-苯甲酸4-胍基-丁酰酯在医学中的新应用 |